// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

COPD exacerbations significantly impact quality of life as measured by SGRQ-C total score: results from the FLAME study

Nicolas Roche - European Respiratory Society (ERS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

Gene signatures from U-BIOPRED transcriptomic-associated clusters exist in COPD

Stelios Pavlidis - European Respiratory Society (ERS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Chronic obstructive pulmonary disease

N/A

Fevipiprant reduces airway smooth muscle mass in asthmatics via PGD2 receptor antagonism

Ruth Saunders - European Respiratory Society (ERS) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Fevipiprant

Late Breaking Abstract - The duration of anti-inflammatory action of fluticasone furoate (FF) assessed via exhaled nitric oxide (FeNO) in asthmatics following administration of FF/vilanterol (VI)

Peter Daley-Yates - European Respiratory Society (ERS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

Fluticasone furoate

Molecular evidence of Group 1 innate lymphoid cell activation in the U-BIOPRED cohort

Stelios Pavlidis - European Respiratory Society (ERS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

Immunol

Real-world study to evaluate the safety and effectiveness of fluticasone propionate/formoterol (FP/FORM) in patients with asthma

Vibeke Backer - European Respiratory Society (ERS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

Fluticasone propionate

Characteristics of eosinophilic severe asthmatics in the Wessex Severe Asthma Cohort (WSAC)

Thomas Jones - European Respiratory Society (ERS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

N/A

Investigating asthma comorbidities: a systematic scoping review

Karim El Ferkh - European Respiratory Society (ERS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

N/A

Atopic Sensitisation of the Isle of Wight Birth Cohort at 26 Years

Claire Hodgekiss - European Respiratory Society (ERS) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Risk factors for severe exacerbations in a real-life population of adults with severe refractory asthma

Rekha Chaudhuri - European Respiratory Society (ERS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

N/A

Zoonotic exposure to helminths is associated with allergic sensitization in a Norwegian population

nils oskar jogi - European Respiratory Society (ERS) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Novel inhaled delivery of anti-IL-13 mAb (Fab fragment): preclinical efficacy in allergic asthma

Neil Gozzard - European Respiratory Society (ERS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

N/A

Asthma control using fluticasone propionate/salmeterol: GOAL study re-analysis using GINA 2016 guidelines

Jean Bousquet - European Respiratory Society (ERS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

Advair HFA

Bronchiectasis disease relevant PAMPs stimulate VEGF and neutrophil elastase release from neutrophils

Christopher Cole - European Respiratory Society (ERS) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Elaszym

Increased serum MMP-3 in severe asthma is associated with oral steroid use; data from U-BIOPRED and BIOAIR cohorts

Anna James - European Respiratory Society (ERS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Asthma

Prednisolone

T17 gene asthma signature characterized by sputum neutrophilia and regular use of antibiotics

Marleen van Geest - European Respiratory Society (ERS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

N/A

Platelets roll and adhere to the vascular bed in response to allergen challenge in allergic mice

Sajeel Shah - European Respiratory Society (ERS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Asthma

N/A

Late Breaking Abstract - Long-term safety of pirfenidone in a real-world setting: final results from the prospective, observational PASSPORT registry

Vincent Cottin - European Respiratory Society (ERS) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Pirfenidone

Late Breaking Abstract - The miR-34a/Pdgfra interaction can be targeted to correct defective alveolarization in experimental bronchopulmonary dysplasia

Jordi Ruiz Camp - European Respiratory Society (ERS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Infant Respiratory Distress Syndrome

N/A

Late Breaking Abstract - Comparison of clinical characteristics between severe adult asthmatics in Brazil(ProAR) and Europe(U-BIOPRED)

Alvaro A Cruz - European Respiratory Society (ERS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

SK1211

Copyright © 2026. QuantiNova All rights reserved